3 Stocks Pushing The Health Services Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 69 points (-0.4%) at 18,094 as of Thursday, May 28, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 843 issues advancing vs. 2,162 declining with 143 unchanged.

The Health Services industry currently sits up 0.1% versus the S&P 500, which is down 0.4%. A company within the industry that fell today was Agilent Technologies ( A), up 2.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is up $0.77 (1.8%) to $43.17 on heavy volume. Thus far, 134,811 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 137,500 shares. The stock has ranged in price between $43.06-$43.44 after having opened the day at $43.22 as compared to the previous trading day's close of $42.40.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. Fresenius Medical Care AG & Co. KGaA has a market cap of $25.7 billion and is part of the health care sector. Shares are up 14.2% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Fresenius Medical Care AG & Co. KGaA a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Boston Scientific ( BSX) is up $0.30 (1.7%) to $18.29 on heavy volume. Thus far, 13.0 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 10.0 million shares. The stock has ranged in price between $17.90-$18.36 after having opened the day at $17.95 as compared to the previous trading day's close of $17.99.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Boston Scientific has a market cap of $23.8 billion and is part of the health care sector. Shares are up 35.8% year-to-date as of the close of trading on Wednesday. Currently there are 14 analysts who rate Boston Scientific a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Boston Scientific Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Baxter International ( BAX) is up $0.52 (0.8%) to $67.04 on average volume. Thus far, 2.3 million shares of Baxter International exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $66.79-$67.24 after having opened the day at $66.87 as compared to the previous trading day's close of $66.52.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $36.6 billion and is part of the health care sector. Shares are down 8.5% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate Baxter International a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Baxter International Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit